Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | The success of ibrutinib in treating mantle cell lymphoma (MCL)

Andrew Davies • 9 Jun 2016
EHA 2016
Mantle Cell Lymphoma Ibrutinib

Andrew Davies, MRCP, PhD from University of Southampton, Southampton, UK discusses the pooled analysis of three trials which all analyzed the outcome of mantle cell lymphoma (MCL) patients treated with ibrutinib (NCT01236391, NCT01599949 and NCT01646021). Overall, there were 370 patients with a complete remission (CR) of 20% and an overall response rate (ORR) of 66%. In patients who achieved CR, over 90% were still alive after 2 years. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.

More from Andrew Davies

Novel therapies in NHL: antibody-drug conjugates
Andrew Davies et al. • 17 Oct 2023
1:11
Economic burden of CAR-T therapy from a UK perspective
Andrew Davies • 24 Apr 2023
2:40
Primary analysis of the Phase III TRANSFORM study: liso-cel in second-line LBCL
Andrew Davies • 24 Apr 2023
1:44
REMoDL-B: bortezomib + R-CHOP versus R-CHOP in patients with DLBCL
Andrew Davies • 24 Apr 2023

Related Videos

3:32
BGB-16673, a novel BTK degrader, in patients with R/R B-cell malignancies
John Seymour • 8 Dec 2023
2:25
The future of CAR-T for the treatment of lymphoma
Anna Sureda • 7 Mar 2024
2:40
The impact of CAR-T on the role of SCT in lymphoma
Anna Sureda • 7 Mar 2024
0:44
A case report of CAR-T-related neurotoxicity presenting as delayed aseptic meningitis in MCL
Stefania Bramanti • 17 Feb 2024
The content of VJHemOnc is intended for healthcare professionals